SAB Biotherapeutics (SABS) Total Current Liabilities (2020 - 2026)

SAB Biotherapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $9.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 2.06% year-over-year to $9.9 million; the trailing twelve-month figure through Mar 2026 stood at $9.9 million (up 2.06% YoY), and the FY2025 full-year result was $10.7 million, up 33.86% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $9.9 million, down from $10.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $19.3 million in Q1 2022, with the low at $7.6 million in Q2 2024.
• Historically, Total Current Liabilities has averaged $11.6 million across 5 years, with a median of $10.7 million in 2025.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 23988.3% — and 2023, when it tumbled 46.14%.
• SAB Biotherapeutics' Total Current Liabilities stood at $15.0 million in 2022, then decreased by 27.88% to $10.8 million in 2023, then declined by 26.21% to $8.0 million in 2024, then soared by 33.86% to $10.7 million in 2025, then slipped by 7.76% to $9.9 million in 2026.
• The last three Total Current Liabilities figures came in at $9.9 million (Q1 2026), $10.7 million (Q4 2025), and $10.8 million (Q3 2025), per Business Quant data.